Should I buy or sell SomaLogic stock right now?

5 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for SomaLogic in the last twelve months. There are currently 3 hold ratings and 2 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "hold" SLGC shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in SLGC, but not buy additional shares or sell existing shares. View SLGC analyst ratings or view top-rated stocks .

What is SomaLogic's stock price target for 2024?

5 analysts have issued 1 year price targets for SomaLogic's stock. Their SLGC share price targets range from $2.30 to $7.00. On average, they expect the company's share price to reach $4.26 in the next year. This suggests a possible upside of 53.2% from the stock's current price. View analysts price targets for SLGC or view top-rated stocks among Wall Street analysts .

How have SLGC shares performed in 2023?

SomaLogic's stock was trading at $2.51 at the beginning of 2023. Since then, SLGC shares have increased by 10.8% and is now trading at $2.78. View the best growth stocks for 2023 here .

When is SomaLogic's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, March 26th 2024. View our SLGC earnings forecast .

How were SomaLogic's earnings last quarter?

SomaLogic, Inc. (NASDAQ:SLGC) released its earnings results on Wednesday, November, 8th. The company reported ($0.12) EPS for the quarter, topping the consensus estimate of ($0.17) by $0.05. The business had revenue of $22.05 million for the quarter, compared to analysts' expectations of $20.45 million. SomaLogic had a negative trailing twelve-month return on equity of 24.72% and a negative net margin of 159.54%.

What ETF holds SomaLogic's stock ?

ARK Genomic Revolution ETF holds 13,104,112 shares of SLGC stock, representing 1.22% of its portfolio.

What guidance has SomaLogic issued on next quarter's earnings?

SomaLogic updated its FY 2023 earnings guidance on Friday, October, 6th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $80.00 million-$84.00 million, compared to the consensus revenue estimate of $81.94 million.

Who are SomaLogic's major shareholders?

SomaLogic's stock is owned by a number of retail and institutional investors. Top institutional investors include ARK Investment Management LLC (6.90%), Sumitomo Mitsui Trust Holdings Inc. (4.66%), Barclays PLC (1.38%), Kent Lake Capital LLC (1.03%), Charles Schwab Investment Management Inc. (0.65%) and Zweig DiMenna Associates LLC (0.33%). Insiders that own company stock include Adam Taich, Alison Marie Roelke and Ruben Gutierrez. View institutional ownership trends .

How do I buy shares of SomaLogic?

Shares of SLGC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull , Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here .

Positive News SentimentPositive News

SomaLogic Stock Price, News & Analysis (NASDAQ:SLGC)

$2.78

-0.05 (-1.77%)

(As of 12/4/2023 ET)

Compare

Today's Range: $2.73
▼
$2.91
50-Day Range: $1.76
▼
$2.83
52-Week Range: $1.73
▼
$3.79

Volume: 1.70 million shs
Average Volume: 1.16 million shs
Market Capitalization: $522.83 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $4.26

SomaLogic MarketRank™ Stock Analysis

Analyst Rating: Hold
2.40 Rating Score
Upside/Downside: 53.2% Upside
$4.26 Price Target
Short Interest: Healthy
4.91% of Float Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: N/A
Insider Trading: Selling Shares
$79,754 Sold Last Quarter
Proj. Earnings Growth: Growing
From ($0.59) to ($0.49) Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.47 out of 5 stars

Business Services Sector

99th out of 301 stocks

Commercial Physical Research Industry

6th out of 12 stocks

3.2

Analyst's Opinion

Consensus Rating
SomaLogic has received a consensus rating of Hold. The company's average rating score is 2.40, and is based on 2 buy ratings, 3 hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $4.26, SomaLogic has a forecasted upside of 53.2% from its current price of $2.78.
Amount of Analyst Coverage
SomaLogic has only been the subject of 3 research reports in the past 90 days.

3.0

Short Interest

Percentage of Shares Shorted
4.91% of the float of SomaLogic has been sold short.
Short Interest Ratio / Days to Cover
SomaLogic has a short interest ratio ("days to cover") of 5.1.
Change versus previous month
Short interest in SomaLogic has recently decreased by 1.66%, indicating that investor sentiment is improving.

0.0

Dividend Strength

Dividend Yield
SomaLogic does not currently pay a dividend.
Dividend Growth
SomaLogic does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for SLGC.

3.8

News and Social Media Coverage

News Sentiment
SomaLogic has a news sentiment score of 1.89. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.64 average news sentiment score of Business Services companies.
Search Interest
2 people have searched for SLGC on MarketBeat in the last 30 days. This is an increase of 100% compared to the previous 30 days.
MarketBeat Follows
1 people have added SomaLogic to their MarketBeat watchlist in the last 30 days.

3.3

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, SomaLogic insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $79,754.00 in company stock.
Percentage Held by Insiders
14.90% of the stock of SomaLogic is held by insiders. A high percentage of insider ownership can be a sign of company health.
Percentage Held by Institutions
66.35% of the stock of SomaLogic is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

1.3

Earnings and Valuation

Earnings Growth
Earnings for SomaLogic are expected to grow in the coming year, from ($0.59) to ($0.49) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of SomaLogic is -4.03, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of SomaLogic is -4.03, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
SomaLogic has a P/B Ratio of 0.93. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About SomaLogic Stock (NASDAQ:SLGC)

SomaLogic, Inc. operates as a protein biomarker discovery and clinical diagnostics company in the United States. It develops slow off-rate modified aptamers (SOMAmers), which are modified nucleic acid-based protein binding reagents that are specific for its cognate protein; and offers proprietary SomaScan services, which provide multiplex protein detection and quantification of protein levels in complex biological samples. The company's SOMAmers/SomaScan technology enables researchers to analyze various biological samples for protein biomarker signatures, which are utilized in drug discovery and development. Its SomaScan's biomarker discoveries use in diagnostic applications for various diseases, including cardiovascular and metabolic disease, nonalcoholic steatohepatitis, wellness, and others. The company also provides SomaSignal, a laboratory-developed test. It serves pharmaceutical and biotechnology companies, and academic and government research institutions. The company has a collaboration agreement with Illumina Cambridge, Ltd for the development of co-branded NGS-based proteomic distributable kits. The company was founded in 1999 and is headquartered in Boulder, Colorado.

SLGC Stock Price History

30 days | 90 days | 365 days | Advanced Chart

SLGC Stock News Headlines

November 22, 2023 | morningstar.com

SomaLogic Inc Class A

November 22, 2023 | finance.yahoo.com

With 54% ownership of the shares, SomaLogic, Inc. (NASDAQ:SLGC) is heavily dominated by institutional owners

December 4, 2023 | DTI Trader (Ad)

New CBOE “special perk” helps traders target income every weekend

You might not immediately realize what you’re reading. Let me help you out a little… What you're looking at is a “special perk” set up by the Chicago Board of Options Exchange.

November 12, 2023 | finance.yahoo.com

SomaLogic, Inc. (NASDAQ:SLGC) Q3 2023 Earnings Call Transcript

November 10, 2023 | markets.businessinsider.com

Hold Rating Maintained for SomaLogic Amidst Strong Performance and Pending LAB Acquisition

November 8, 2023 | benzinga.com

Recap: SomaLogic Q3 Earnings

November 1, 2023 | finance.yahoo.com

SomaLogic announces new SomaScan® 11K Platform

October 5, 2023 | markets.businessinsider.com

Hold Rating on SomaLogic Post-Merger: A Strategic Move Shadowed by Stock Performance Uncertainty

December 4, 2023 | Wealthpress (Ad)

Trading Experts Call It “The Perfect Tesla Trade”

Thanks to a new discovery linked to shares of Tesla, regular folks can now target gains of 100% or more in six days or less. New research shows it’s happened 23 different times this year. The next trade is scheduled for this Thursday.

October 5, 2023 | markets.businessinsider.com

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates SLGC, APRN, FNCB

October 4, 2023 | msn.com

Why SomaLogic Stock Dived by 10% on Wednesday

October 4, 2023 | benzinga.com

Shareholder Alert: Ademi LLP investigates whether SomaLogic, Inc. has obtained a Fair Price in its transaction with Standard BioTools

October 4, 2023 | benzinga.com

SLGC Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of SomaLogic, Inc. Is Fair to Shareholders

October 4, 2023 | finance.yahoo.com

Standard BioTools and SomaLogic to Combine in All-Stock Merger Creating a Diversified Leader in Life Sciences Tools

September 19, 2023 | finance.yahoo.com

SomaLogic and Korea’s DNA Link partner to bring the 7,000-plex SomaScan® platform to the fast-growing Asia-Pacific proteomics market

September 12, 2023 | stockhouse.com

SomaLogic researchers identify key proteins to aid in early detection of lung, colon and breast cancer and ovarian tumors

September 5, 2023 | stockhouse.com

SomaLogic expands agreement with Novo Nordisk to 2025

August 18, 2023 | finance.yahoo.com

SomaLogic, Inc. (NASDAQ:SLGC) Just Reported Earnings, And Analysts Cut Their Target Price

August 17, 2023 | finance.yahoo.com

SomaLogic, Inc. (NASDAQ:SLGC) Q2 2023 Earnings Call Transcript

August 15, 2023 | seekingalpha.com

Company Calendar

Last Earnings: 11/08/2023
Today: 12/04/2023
Fiscal Year End: 12/31/2023
Next Earnings (Estimated): 3/26/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Commercial physical research
Sub-Industry: N/A
Sector: Business Services
Current Symbol: NASDAQ:SLGC
CUSIP: N/A
CIK: 1837412
Web: ii.cmlifesciencesspac.com
Phone: 303-625-9000
Fax: N/A
Employees: 451
Year Founded: N/A

Price Target and Rating

Average Stock Price Target: $4.26
High Stock Price Target: $7.00
Low Stock Price Target: $2.30
Potential Upside/Downside: +53.2%
Consensus Rating: Hold
Rating Score (0-4): 2.40
Research Coverage: 5 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($0.69)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-109,160,000.00
Net Margins: -159.54%
Pretax Margin: -159.08%
Return on Equity: -24.72%
Return on Assets: -21.62%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 17.79
Quick Ratio: 17.29

Sales & Book Value

Annual Sales: $97.67 million
Price / Sales: 5.35
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $3.00 per share
Price / Book: 0.93

Miscellaneous

Outstanding Shares: 188,070,000
Free Float: 160,049,000
Market Cap: $522.83 million
Optionable: Not Optionable
Beta: 1.69

7 Energy Stocks to Buy and Hold Forever

Do you expect the global demand for energy to shrink?! If not, it's time to take a look at how energy stocks can play a part in your portfolio.

Get This Free Report

Key Executives

Dr. Stephen A. Williams BS (Age 63)
MB, Ph.D., Chief Medical Officer
Comp: $648.03k
Mr. Adam Taich (Age 48)
Interim CEO
Mr. Eliot M. Lurier CPA (Age 65)
Interim Chief Financial Officer
Mr. Pi Zheng (Age 50)
Interim Chief Accounting Officer
Dr. Jason Cleveland Ph.D.
Chief Technology Officer
Dr. Nebojsa Janjic Ph.D. (Age 62)
Chief Science Officer
Mr. Ruben Gutierrez J.D. (Age 48)
General Counsel
Ms. Alison Marie Roelke (Age 48)
Chief People Officer
Dr. Shane Bowen Ph.D.
Chief Research & Development Officer

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

SLGC Stock Analysis - Frequently Asked Questions

Should I buy or sell SomaLogic stock right now?: 5 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for SomaLogic in the last twelve months. There are currently 3 hold ratings and 2 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "hold" SLGC shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in SLGC, but not buy additional shares or sell existing shares.
View SLGC analyst ratings or view top-rated stocks.
What is SomaLogic's stock price target for 2024?: 5 analysts have issued 1 year price targets for SomaLogic's stock. Their SLGC share price targets range from $2.30 to $7.00. On average, they expect the company's share price to reach $4.26 in the next year. This suggests a possible upside of 53.2% from the stock's current price.
View analysts price targets for SLGC or view top-rated stocks among Wall Street analysts.
How have SLGC shares performed in 2023?: SomaLogic's stock was trading at $2.51 at the beginning of 2023. Since then, SLGC shares have increased by 10.8% and is now trading at $2.78.
View the best growth stocks for 2023 here.
When is SomaLogic's next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Tuesday, March 26th 2024.
View our SLGC earnings forecast.
How were SomaLogic's earnings last quarter?: SomaLogic, Inc. (NASDAQ:SLGC) released its earnings results on Wednesday, November, 8th. The company reported ($0.12) EPS for the quarter, topping the consensus estimate of ($0.17) by $0.05. The business had revenue of $22.05 million for the quarter, compared to analysts' expectations of $20.45 million. SomaLogic had a negative trailing twelve-month return on equity of 24.72% and a negative net margin of 159.54%.

What ETF holds SomaLogic's stock ?: ARK Genomic Revolution ETF holds 13,104,112 shares of SLGC stock, representing 1.22% of its portfolio.
What guidance has SomaLogic issued on next quarter's earnings?: SomaLogic updated its FY 2023 earnings guidance on Friday, October, 6th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $80.00 million-$84.00 million, compared to the consensus revenue estimate of $81.94 million.
Who are SomaLogic's major shareholders?: SomaLogic's stock is owned by a number of retail and institutional investors. Top institutional investors include ARK Investment Management LLC (6.90%), Sumitomo Mitsui Trust Holdings Inc. (4.66%), Barclays PLC (1.38%), Kent Lake Capital LLC (1.03%), Charles Schwab Investment Management Inc. (0.65%) and Zweig DiMenna Associates LLC (0.33%). Insiders that own company stock include Adam Taich, Alison Marie Roelke and Ruben Gutierrez.
View institutional ownership trends.
How do I buy shares of SomaLogic?: Shares of SLGC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

This page (NASDAQ:SLGC) was last updated on 12/4/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial